Crispr Therapeutics [CRSP] vs Vertex [VRTX] Detailed Stock Comparison
Crispr Therapeutics
NASDAQ
Loading...
Vertex
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Crispr Therapeutics wins in 6 metrics, Vertex wins in 11 metrics, with 0 ties. Vertex appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Crispr Therapeutics | Vertex | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -15.61 | 28.68 | Crispr Therapeutics |
| Price-to-Book Ratio | 3.50 | 6.02 | Crispr Therapeutics |
| Debt-to-Equity Ratio | 12.59 | 8.89 | Vertex |
| PEG Ratio | -0.26 | -0.22 | Crispr Therapeutics |
| EV/EBITDA | -10.65 | 20.53 | Crispr Therapeutics |
| Profit Margin (TTM) | -215.00% | 31.86% | Vertex |
| Operating Margin (TTM) | -14,918.27% | 38.93% | Vertex |
| EBITDA Margin (TTM) | N/A | 38.93% | N/A |
| Return on Equity | -25.34% | 22.77% | Vertex |
| Return on Assets (TTM) | -13.05% | 13.09% | Vertex |
| Free Cash Flow (TTM) | $-144.68M | $-978.00M | Crispr Therapeutics |
| 1-Year Return | 49.82% | -16.36% | Crispr Therapeutics |
| Price-to-Sales Ratio (TTM) | 161.92 | 9.06 | Vertex |
| Enterprise Value | $4.66B | $98.55B | Vertex |
| EV/Revenue Ratio | 122.34 | 8.63 | Vertex |
| Gross Profit Margin (TTM) | N/A | 86.25% | N/A |
| Revenue per Share (TTM) | $0 | $44 | Vertex |
| Earnings per Share (Diluted) | $-5.40 | $14.06 | Vertex |
| Beta (Stock Volatility) | 1.84 | 0.43 | Vertex |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Crispr Therapeutics vs Vertex Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Crispr Therapeutics | 0.57% | 10.07% | 29.74% | 37.12% | 116.77% | 69.42% |
| Vertex | 1.82% | 1.92% | 1.94% | -12.30% | -15.10% | -0.70% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Crispr Therapeutics | 49.82% | 29.81% | -36.09% | 407.89% | 407.89% | 407.89% |
| Vertex | -16.36% | 37.41% | 84.75% | 252.43% | 1,018.23% | 1,674.89% |
News Based Sentiment: Crispr Therapeutics vs Vertex
Crispr Therapeutics
News based Sentiment: MIXED
October presented a mixed bag for CRISPR Therapeutics, with encouraging sales growth for Casgevy and promising pipeline developments offset by continued financial losses and a challenging earnings outlook. The company is making progress, but significant hurdles remain in achieving profitability and sustained growth.
Vertex
News based Sentiment: MIXED
October presented a mixed bag for Vertex, with a major FDA approval and positive financial results offset by a failed clinical trial and increased operating expenses. The strategic pipeline advancements and strong financial position suggest continued growth potential, but investors should monitor the impact of the trial setback and expense increases.
Performance & Financial Health Analysis: Crispr Therapeutics vs Vertex
| Metric | CRSP | VRTX |
|---|---|---|
| Market Information | ||
| Market Cap | $6.24B | $103.40B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 2,514,739 | 1,835,420 |
| 90 Day Avg. Volume | 2,285,110 | 1,652,450 |
| Last Close | $70.59 | $410.25 |
| 52 Week Range | $30.04 - $73.95 | $362.50 - $519.88 |
| % from 52W High | -4.54% | -21.09% |
| All-Time High | $220.20 (Jan 11, 2021) | $519.88 (Nov 04, 2024) |
| % from All-Time High | -67.94% | -21.09% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.73% | 0.12% |
| Quarterly Earnings Growth | N/A | 0.12% |
| Financial Health | ||
| Profit Margin (TTM) | -2.15% | 0.32% |
| Operating Margin (TTM) | -149.18% | 0.39% |
| Return on Equity (TTM) | -0.25% | 0.23% |
| Debt to Equity (MRQ) | 12.59 | 8.89 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $19.36 | $67.02 |
| Cash per Share (MRQ) | $18.93 | $24.90 |
| Operating Cash Flow (TTM) | $-324,771,008 | $3.85B |
| Levered Free Cash Flow (TTM) | $-239,332,128 | $2.91B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Crispr Therapeutics vs Vertex
| Metric | CRSP | VRTX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -15.61 | 28.68 |
| Forward P/E | -13.44 | 21.49 |
| PEG Ratio | -0.26 | -0.22 |
| Price to Sales (TTM) | 161.92 | 9.06 |
| Price to Book (MRQ) | 3.50 | 6.02 |
| Market Capitalization | ||
| Market Capitalization | $6.24B | $103.40B |
| Enterprise Value | $4.66B | $98.55B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 122.34 | 8.63 |
| Enterprise to EBITDA | -10.65 | 20.53 |
| Risk & Other Metrics | ||
| Beta | 1.84 | 0.43 |
| Book Value per Share (MRQ) | $19.36 | $67.02 |
Financial Statements Comparison: Crispr Therapeutics vs Vertex
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CRSP | VRTX |
|---|---|---|
| Revenue/Sales | $0 | $2.96B |
| Cost of Goods Sold | $57.51M | $407.50M |
| Gross Profit | $-57.51M | $2.56B |
| Research & Development | $72.48M | $978.40M |
| Operating Income (EBIT) | $-148.42M | $1.15B |
| EBITDA | $-143.69M | $1.34B |
| Pre-Tax Income | $-134.89M | $1.28B |
| Income Tax | $1.11M | $250.10M |
| Net Income (Profit) | $-136.00M | $1.03B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CRSP | VRTX |
|---|---|---|
| Cash & Equivalents | $235.18M | $4.67B |
| Total Current Assets | $1.87B | $10.01B |
| Total Current Liabilities | $119.45M | $3.78B |
| Long-Term Debt | $201.85M | $1.65B |
| Total Shareholders Equity | $1.83B | $16.50B |
| Retained Earnings | $-1.50B | $10.25B |
| Property, Plant & Equipment | $182.48M | $2.63B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CRSP | VRTX |
|---|---|---|
| Operating Cash Flow | $-96.31M | $404.90M |
| Capital Expenditures | $-206,000 | $-40.70M |
| Free Cash Flow | $-54.15M | $778.20M |
| Debt Repayment | N/A | $-1.30M |
| Common Stock Repurchase | N/A | $-696.60M |
Short Interest & Institutional Ownership Analysis
| Metric | CRSP | VRTX |
|---|---|---|
| Shares Short | 23.81M | 4.05M |
| Short Ratio | 12.64 | 2.83 |
| Short % of Float | 0.30% | 0.02% |
| Average Daily Volume (10 Day) | 2,514,739 | 1,835,420 |
| Average Daily Volume (90 Day) | 2,285,110 | 1,652,450 |
| Shares Outstanding | 85.74M | 256.94M |
| Float Shares | 90.51M | 255.58M |
| % Held by Insiders | 0.02% | 0.00% |
| % Held by Institutions | 0.81% | 0.98% |
Dividend Analysis & Yield Comparison: Crispr Therapeutics vs Vertex
| Metric | CRSP | VRTX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |